Characterization of the protein ubiquitination response induced by Doxorubicin

FEBS Journal

Volumn 279, Issue 12, 2012, Pages 2182-2191

  Mandili, Giorgia ^a   Khadjavi, Amina ^a   Gallo, Valentina ^a   Minero, Valerio G ^a   Bessone, Luca ^a   Carta, Franco ^b   Giribaldi, Giuliana ^a   Turrini, Francesco ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Nurex SRL   (Italy)

Author keywords

cancer; Doxorubicin; neuroblastoma; proteomics; ubiquitinated proteins

Indexed keywords

ALPHA ENOLASE; BORTEZOMIB; DOXORUBICIN; HEAT SHOCK PROTEIN 27; LACTATE DEHYDROGENASE; PROTEASOME;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN DENATURATION; PROTEIN DEPLETION; PROTEIN SYNTHESIS INHIBITION; UBIQUITINATION;

BLOTTING, WESTERN; BORONIC ACIDS; CELL LINE, TUMOR; DOXORUBICIN; HSP27 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPRECIPITATION; L-LACTATE DEHYDROGENASE; PHOSPHOPYRUVATE HYDRATASE; PYRAZINES; UBIQUITINATION;

EID: 84861866354     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2012.08602.x     Document Type: Article

References (35)

1. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias M, et al. (2006) Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst 98, 1142-1157.
2. Blanc E, Goldschneider D, Ferrandis E, Barrois M, Le Roux G, Leonce S, Douc-Rasy S, Bénard J, &, Raguénez G, (2003) MYCN enhances P-gp/MDR1 gene expression in the human metastatic neuroblastoma IGR-N-91 model. Am J Pathol 163, 321-331.
3. Ho R, Eggert A, Hishiki T, Minturn J, Ikegaki N, Foster P, Camoratto A, Evans A, &, Brodeur G, (2002) Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 62, 6462-6466.
4. LoConte N, Thomas J, Alberti D, Heideman J, Binger K, Marnocha R, Utecht K, Geiger P, Eickhoff J, Wilding G, et al. (2008) A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer. Cancer Chemother Pharmacol 63, 109-115.
5. Dees E, O'Neil B, Lindley C, Collichio F, Carey L, Collins J, Riordan W, Ivanova A, Esseltine D, &, Orlowski R, (2008) A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemother Pharmacol 63, 99-107.
6. Cummings J, Willmott N, Hoey B, Marley E, &, Smyth J, (1992) The consequences of doxorubicin quinone reduction in vivo in tumour tissue. Biochem Pharmacol 44, 2165-2174.
7. Benchekroun M, Pourquier P, Schott B, &, Robert J, (1993) doxorubicin-induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin. Eur J Biochem 211, 141-146.
8. Huang R, Kowalski D, Minderman H, Gandhi N, &, Johnson E, (2007) Small ubiquitin-related modifier pathway is a major determinant of doxorubicin cytotoxicity in Saccharomyces cerevisiae. Cancer Res 67, 765-772.
9. Yamamoto Y, Hoshino Y, Ito T, Nariai T, Mohri T, Obana M, Hayata N, Uozumi Y, Maeda M, Fujio Y, et al. (2008) Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc Res 79, 89-96.
10. Liu L, Zhang X, Qian B, Min X, &, Cheng Y, (2008) Heat shock protein 27 attenuated doxorubicin-induced myocardial damage by reducing cardiomyocyte apoptosis, mitochondria damage and protein carbonylation. Zhonghua Xin Xue Guan Bing Za Zhi 36, 1021-1026 (in Chinese).
11. Zanini C, Giribaldi G, Mandili G, Carta F, Crescenzio N, Bisaro B, Doria A, Foglia L, di Montezemolo L, Timeus F, et al. (2007) Inhibition of heat shock proteins (HSP) expression by quercetin and differential doxorubicin sensitization in neuroblastoma and Ewing's sarcoma cell lines. J Neurochem 103, 1344-1354.
12. Mosser D, &, Morimoto R, (2004) Molecular chaperones and the stress of oncogenesis. Oncogene 23, 2907-2918.
13. Murata S, Chiba T, &, Tanaka K, (2003) CHIP: a quality-control E3 ligase collaborating with molecular chaperones. Int J Biochem Cell Biol 35, 572-578.
14. Tan F, Lu L, Cai Y, Wang J, Xie Y, Wang L, Gong Y, Xu B, Wu J, Luo Y, et al. (2008) Proteomic analysis of ubiquitinated proteins in normal hepatocyte cell line Chang liver cells. Proteomics 8, 2885-2896.
15. Kirkpatrick DS, Denison C, &, Gygi SP, (2005) Weighing in on ubiquitin: the expanding role of mass-spectrometry-based proteomics. Nat Cell Biol 7, 750-757.
16. Layfield R, Tooth D, Landon M, Dawson S, Mayer J, &, Alban A, (2001) Purification of poly-ubiquitinated proteins by S5a-affinity chromatography. Proteomics 1, 773-777.
17. Khan T, Stauffer J, Williams R, Hixon J, Salcedo R, Lincoln E, Back T, Powell D, Lockett S, Arnold A, et al. (2006) Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors. J Immunol 176, 6302-6312.
18. Bersani F, Taulli R, Accornero P, Morotti A, Miretti S, Crepaldi T, &, Ponzetto C, (2008) Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur J Cancer 44, 876-884.
19. Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse C, Paul C, Wieske M, Arrigo A, Buchner J, et al. (1999) Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor α by phosphorylation. J Biol Chem 274, 18947-18956.
20. Bar-On O, Shapira M, &, Hershko DD, (2007) Differential effects of doxorubicin treatment on cell cycle arrest and Skp2 expression in breast cancer cells. Anticancer Drugs 18, 1113-1121.
21. Fekete MR, McBride WH, &, Pajonk F, (2005) Anthracyclines, proteasome activity and multi-drug-resistance. BMC Cancer 5, 114.
22. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, et al. (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99, 14374-14379.
23. Shin Y, Klucken J, Patterson C, Hyman B, &, McLean P, (2005) The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates α-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem 280, 23727-23734.
24. McDonough H, &, Patterson C, (2003) CHIP: a link between the chaperone and proteasome systems. Cell Stress Chaperones 8, 303-308.
25. Qian S, McDonough H, Boellmann F, Cyr D, &, Patterson C, (2006) CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature 440, 551-555.
26. Kumar P, Ambasta R, Veereshwarayya V, Rosen K, Kosik K, Band H, Mestril R, Patterson C, &, Querfurth H, (2007) CHIP and HSPs interact with β-APP in a proteasome-dependent manner and influence Aβ metabolism. Hum Mol Genet 16, 848-864.
27. Wang M, Ye R, Barron E, Baumeister P, Mao C, Luo S, Fu Y, Luo B, Dubeau L, Hinton D, et al. (2010) Essential role of the unfolded protein response regulator GRP78/BiP in protection from neuronal apoptosis. Cell Death Differ 17, 488-498.
28. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, &, Kroemer G, (2006) Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5, 2592-2601.
29. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, &, Gudkov AV, (2011) Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. Oncotarget 2, 209-221.
30. Armstrong M, Schumacher K, Mody R, Yanik G, Opipari AJ, &, Castle V, (2008) Bortezomib as a therapeutic candidate for neuroblastoma. J Exp Ther Oncol 7, 135-145.
31. Te Kronnie G, Timeus F, Rinaldi A, Crescenzio N, Spinelli M, Rosolen A, Ricotti E, &, Basso G, (2004) Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition. Int J Mol Med 14, 373-382.
32. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
33. Mastrocola R, Reffo P, Penna F, Tomasinelli C, Boccuzzi G, Baccino F, Aragno M, &, Costelli P, (2008) Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress. Free Radic Biol Med 44, 584-593.
34. Barbero G, Carta F, Giribaldi G, Mandili G, Crobu S, Ceruti C, Fontana D, Destefanis P, &, Turrini F, (2006) Protein/RNA coextraction and small two-dimensional polyacrylamide gel electrophoresis for proteomic/gene expression analysis of renal cancer biopsies. Anal Biochem 349, 62-71.
35. Aina V, Perardi A, Bergandi L, Malavasi G, Menabue L, Morterra C, &, Ghigo D, (2007) Cytotoxicity of zinc-containing bioactive glasses in contact with human osteoblasts. Chem Biol Interact 167, 207-218.